Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it ...

Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicated subsidiary company to ...

KING OF PRUSSIA, Pa., Sept. 12, 2024 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotechnology company focused on harnessing and engineering Molecular Glues for targeted protein ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.

Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

Created Through Collaborative Research Between Eisai and PRISM TOKYO, Sept. 8, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company ...

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act.

Eisai is “working collaboratively” with NICE, the Scottish Medicines Consortium and the NHS to make Leqembi available to eligible patients as soon as possible, the company said in a statement ...

Although Eisai's target for global Leqembi sales is an ambitious ¥56.5 billion for FY3/25, UBS forecasts sales to reach ¥59 billion, exceeding the company's goal. This projection has been revised ...